Filing Details
- Accession Number:
- 0000078003-25-000074
- Form Type:
- 13D Filing
- Publication Date:
- 2025-03-19 20:00:00
- Filed By:
- Pfizer Inc.
- Company:
- Haleon Plc
- Filing Date:
- 2025-03-20
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | 661,709,764 | 0 | 661,709,764 | 0 | 661,709,764 | 7.3% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 14)
|
Haleon plc (Name of Issuer) |
Ordinary Shares, nominal value GBP0.01 per share (Title of Class of Securities) |
405552100 (CUSIP Number) |
Margaret M. Madden, Esq. Pfizer Inc., 66 Hudson Boulevard East New York, NY, 10001 212-733-2323 Jacob A. Kling, Esq. Wachtell, Lipton, Rosen & Katz, 51 West 52nd Street New York, NY, 10019 212-403-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
03/18/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 405552100 |
| 1 |
Name of reporting person
Pfizer Inc. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
661,709,764.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
7.3 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person:
661,709,764 Ordinary Shares includes: (1) 661,709,764 Ordinary Shares, nominal value GBP0.01 per share ("Ordinary Shares"), of Haleon plc (the "Issuer"), held on behalf of Pfizer Inc. ("Pfizer" or the "Reporting Person") by Pfizer's nominee and (2) zero American Depositary Shares. See Item 5.
Percent of class represented by amount in row (11) is calculated based upon 9,054,145,714 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer on its Form 6-K filed with the Securities and Exchange Commission (the "SEC") on February 3, 2025.
The CUSIP on the cover page applies to the Issuer's American Depositary Shares, each representing two Ordinary Shares. No CUSIP has been assigned to the Ordinary Shares.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Ordinary Shares, nominal value GBP0.01 per share | |
| (b) | Name of Issuer:
Haleon plc | |
| (c) | Address of Issuer's Principal Executive Offices:
Building 5, First Floor, The Heights, Weybridge, Surrey,
UNITED KINGDOM
, KT13 0NY. | |
Item 1 Comment:
Explanatory Note
The following constitutes Amendment No. 14 ("Amendment No. 14") to the Schedule 13D filed with the SEC by Pfizer on July 27, 2022, as amended by Amendment No. 1 on February 1, 2023, Amendment No. 2 on May 15, 2023, Amendment No. 3 on September 11, 2023, Amendment No. 4 on October 10, 2023, Amendment No. 5 on January 19, 2024, Amendment No. 6 on March 19, 2024, Amendment No. 7 on March 22, 2024, Amendment No. 8 on July 29, 2024, Amendment No. 9 on October 1, 2024, Amendment No. 10 on October 3, 2024, Amendment No. 11 on January 16, 2025, Amendment No. 12 on January 21, 2025 and Amendment No. 13 on Februrary 27, 2025 (the "Schedule 13D"). This Amendment No. 14 amends and supplements the Schedule 13D as specifically set forth herein. Except as set forth herein, the Schedule 13D is unmodified. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. | ||
| Item 2. | Identity and Background | |
| (a) | No amendment to this Item is being made. | |
| (b) | No amendment to this Item is being made. | |
| (c) | No amendment to this Item is being made. | |
| (d) | No amendment to this Item is being made. | |
| (e) | No amendment to this Item is being made. | |
| (f) | No amendment to this Item is being made. | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
No amendment to this Item is being made. | ||
| Item 4. | Purpose of Transaction | |
Item 4 of the Schedule 13D is hereby supplemented as follows:
Following the closing of the March 2025 Secondary Offering and the March 2025 Share Buyback (each as defined in Item 6), Pfizer will cease to beneficially own Ordinary Shares of Haleon. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The first and second paragraphs of Item 5 of the Schedule 13D are hereby superseded by the following paragraphs:
As of the date of this Schedule 13D, without giving effect to the March 2025 Secondary Offering or the March 2025 Share Buyback, Pfizer is the beneficial owner of 661,709,764 Ordinary Shares, which represents approximately 7.3% of the Issuer's outstanding Ordinary Shares. Pfizer's beneficial ownership is composed of (1) 661,709,764 Ordinary Shares held on behalf of Pfizer by Pfizer's nominee and (2) zero American Depositary Shares. The beneficial ownership percentage reported herein was calculated based on 9,054,145,714 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer on its Form 6-K filed with the SEC on February 3, 2025.
The number of Ordinary Shares as to which the Reporting Person has the sole power to vote or direct the vote is 661,709,764. The number of Ordinary Shares as to which the Reporting Person shares the power to vote or direct the vote is zero. The number of Ordinary Shares as to which the Reporting Person has the sole power to dispose or direct the disposition is 661,709,764. The number of Ordinary Shares as to which the Reporting Person shares the power to dispose or direct the disposition is zero. | |
| (b) | See (a). | |
| (c) | No amendment to this Item is being made. | |
| (d) | No amendment to this Item is being made. | |
| (e) | No amendment to this Item is being made. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
The information set forth under the caption "July 2024 Share Purchase Deed" within Item 6 of Schedule 13D is hereby supplemented by the information set forth below under the caption "July 2024 Share Purchase Deed," and Item 6 of the Schedule 13D is hereby supplemented by the information set forth below under the caption "March 2025 Secondary Offering."
July 2024 Share Purchase Deed
Subject to the terms and conditions of the July 2024 Share Purchase Deed, in connection with the March 2025 Secondary Offering, the Issuer has agreed to purchase Ordinary Shares from Pfizer, and Pfizer has agreed to sell Ordinary Shares to the Issuer, having an aggregate purchase price of approximately GBP170 million (approximately $220 million) (such transaction, the "March 2025 Share Buyback"). The purchase price per Ordinary Share in the March 2025 Share Buyback will be equal to the offering price per Ordinary Share in the March 2025 Secondary Offering. Accordingly, a total of approximately 44 million Ordinary Shares will be repurchased by the Issuer pursuant to the March 2025 Share Buyback. The March 2025 Share Buyback is conditioned on, among other things, the closing of the March 2025 Secondary Offering. The March 2025 Share Buyback is expected to close at the same time as, or as soon as reasonably practicable following, the closing of the March 2025 Secondary Offering, which is expected to be completed on March 21, 2025, subject to the conditions set forth in the March 2025 Block Trade Agreement (as defined herein).
The foregoing description of the July 2024 Share Purchase Deed does not purport to be complete and is qualified in its entirety by reference to the actual terms of such agreement, which is filed as Exhibit 99.1 to Amendment No. 8 and is incorporated by reference herein.
March 2025 Secondary Offering
On March 18, 2025, Pfizer, as the seller, entered into a secondary block trade agreement (the "March 2025 Block Trade Agreement") with Citigroup Global Markets Limited, Goldman Sachs International, Merrill Lynch International, Deutsche Bank AG, acting through its London Branch (which is trading for these purposes as Deutsche Numis), and Barclays Bank PLC as the lead managers (the "Lead Managers"), and the additional managers named therein (together with the Lead Managers, the "Managers"), pursuant to which the Lead Managers agreed, severally and not jointly or jointly and severally, to use their respective reasonable endeavors to procure purchasers for 661,709,764 Ordinary Shares (or such other number as agreed between Pfizer and the Lead Managers) at a price to be determined pursuant to an accelerated bookbuilding process (the "March 2025 Secondary Offering"), and the Managers excluding the Lead Managers agreed, severally and not jointly or jointly and severally, to act as co-managers in connection with the March 2025 Secondary Offering. Pursuant to the terms of sale dated March 19, 2025 (the "Terms of Sale"), the number of Ordinary Shares to be sold was determined to be 617,553,920 at a price of 385 pence (approximately $5.01) per Ordinary Share. Such Ordinary Shares will be sold in an unregistered offering pursuant to exemptions from registration under the Securities Act of 1933, as amended. The March 2025 Secondary Offering is expected to close on March 21, 2025, subject to the conditions set forth in the March 2025 Block Trade Agreement.
The foregoing descriptions of the March 2025 Block Trade Agreement and the Terms of Sale do not purport to be complete and are qualified in their entirety by reference to the actual terms of such agreements, which are filed as Exhibit 99.2 and Exhibit 99.3 to this Amendment No. 14 and are incorporated by reference herein. | ||
| Item 7. | Material to be Filed as Exhibits. | |
99.1 Share Purchase Deed, dated as of July 29, 2024, by and between Pfizer Inc. and the Issuer (incorporated by reference to Exhibit 99.1 to Amendment No. 8).
99.2 Secondary Block Trade Agreement, dated as of March 18, 2025, by and among Pfizer Inc., Citigroup Global Markets Limited, Goldman Sachs International, Merrill Lynch International, Deutsche Bank AG, acting through its London Branch (which is trading for these purposes as Deutsche Numis), Barclays Bank PLC, RBC Europe Limited, J.P. Morgan Securities plc, Morgan Stanley & Co. International plc and Independence Point Securities LLC.
99.3 Terms of Sale, dated as of March 19, 2025, by and among Pfizer Inc., Citigroup Global Markets Limited, Goldman Sachs International, Merrill Lynch International, Deutsche Bank AG, acting through its London Branch (which is trading for these purposes as Deutsche Numis), Barclays Bank PLC, RBC Europe Limited, J.P. Morgan Securities plc, Morgan Stanley & Co. International plc and Independence Point Securities LLC. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|